融捷健康(300247) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥94,523,466.14, a decrease of 4.88% compared to the same period last year[6]. - Net profit attributable to shareholders was ¥3,713,105.90, down 82.70% year-on-year, while the net profit after deducting non-recurring gains and losses was ¥4,092,591.56, a decrease of 4.57%[6]. - Total revenue for the third quarter of 2022 was CNY 330,663,140.51, a decrease of 10.1% compared to CNY 367,789,975.05 in the same period last year[21]. - The net profit for Q3 2022 was CNY 146,229,493.28, a significant increase from CNY 36,549,298.46 in Q3 2021, representing a growth of 300.5%[22]. - The company reported an operating profit of CNY 154,732,798.88, compared to CNY 42,036,052.00 in the same period last year, marking an increase of 268.5%[22]. - The total comprehensive income for the quarter was CNY 191,420,496.12, compared to CNY 33,487,828.02 in Q3 2021, an increase of 471.5%[23]. - Basic and diluted earnings per share were both CNY 0.1718, up from CNY 0.0376 in the same quarter last year, representing an increase of 356.4%[23]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,200,763,730.47, an increase of 17.47% from the end of the previous year[6]. - Total assets as of September 30, 2022, amounted to CNY 1,200,763,730.47, an increase from CNY 1,022,175,500.47 at the start of the year[19]. - The total liabilities decreased to CNY 148,204,500.59 from CNY 161,064,333.37, reflecting a reduction of 7.9%[19]. - The company’s equity attributable to shareholders increased by 21.51% to ¥1,010,310,330.80 compared to the previous year[6]. Cash Flow - Cash flow from operating activities showed a net outflow of ¥54,436,363.18, representing an increase of 826.89% compared to the previous period[12]. - The cash flow from operating activities was negative at CNY -54,436,363.18, worsening from CNY -5,873,002.92 in the previous year[24]. - The company experienced a net cash outflow from investing activities of CNY -13,875,248.94, an improvement from CNY -67,490,037.99 in the previous year[25]. Inventory and Expenses - The company’s inventory increased by 40.49% to ¥209,557,516.71, attributed to product purchases by its U.S. subsidiary[9]. - Inventory increased to CNY 209,557,516.71 from CNY 149,163,353.47, marking a rise of 40.5%[18]. - Research and development expenses for the quarter were CNY 7,904,373.99, down from CNY 9,969,905.85, reflecting a decrease of 20.7%[22]. - The company’s financial expenses decreased significantly by 1242.54% to -¥11,406,672.37 due to currency exchange rate fluctuations[11]. Shareholder Information - The number of common shareholders at the end of the reporting period was 38,590, with the largest shareholder holding 14.54% of the shares[14]. - The company has a total of 116,912,302 unrestricted shares held by its largest shareholder, accounting for 14.54% of total shares[15]. Investment Income - The company reported a significant increase in investment income of ¥132,698,822.50, up 1393.25% due to the sale of equity in Zhongsheng Suyuan[11]. Deferred Income - The company’s deferred income decreased by 92.80% to ¥9,447.96 as a result of revenue recognition during the reporting period[10].